Indeed, there are ongoing clinical trials for PI3Kα inhibitors in combination with AKT and mTORC1 inhibitors and/or standard anticancer therapies with promising results in breast cancer and prostate cancer [43,44]. This evidence concerns the gene AKT1 and breast cancer.